SpringWorks Therapeutics Stock

SpringWorks Therapeutics Dividend 2024

SpringWorks Therapeutics Dividend

0 USD

SpringWorks Therapeutics Dividend yield

Ticker

SWTX

ISIN

US85205L1070

WKN

A2PRLN

How much dividend does SpringWorks Therapeutics 2024 pay?

According to the latest status from September 2024, SpringWorks Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current SpringWorks Therapeutics price of 38.75 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical SpringWorks Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the SpringWorks Therapeutics Dividend Safe?

SpringWorks Therapeutics has been increasing the dividend for 0 years.

Over the past 7 years, SpringWorks Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding SpringWorks Therapeutics's Dividend Distributions

SpringWorks Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining SpringWorks Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

SpringWorks Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in SpringWorks Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

SpringWorks Therapeutics Aktienanalyse

What does SpringWorks Therapeutics do?

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative drugs for rare and hard-to-treat diseases. The company was founded by Pfizer Inc. in 2017 and is headquartered in Stamford, Connecticut, USA. Since then, it has become one of the leading companies in the industry and works closely with scientists, doctors, and patients to develop better therapies for rare diseases. The business model of SpringWorks Therapeutics Inc is based on identifying and developing drugs for chronic and severe diseases with currently no satisfactory treatment options. The company places great emphasis on the use of new technologies and scientific knowledge to maximize the effectiveness and safety of its drugs. At the same time, it strives to advance product development as quickly and efficiently as possible in order to offer patients better treatment options as soon as possible. An important part of SpringWorks Therapeutics Inc's business model is partnerships and collaborations with other companies and institutions. The company works closely with other biopharmaceutical and biotechnology companies to accelerate its development plans and maximize the potential of its drugs. It also maintains close relationships with research institutes, such as the National Institutes of Health (NIH), to gain the latest scientific knowledge and translate it into new therapies. SpringWorks Therapeutics Inc specializes in the development of drugs for rare and hard-to-treat diseases. The company focuses on four main areas: oncology, neurology, hematology, and pediatrics. In each of these areas, the company has a number of promising programs and products in development. In the oncology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare and hard-to-treat types of cancer. An important program in this area is the development program for Nirogacestat, a gamma-secretase inhibitor. This program has the potential to provide a new treatment option for patients with T-cell lymphoblastic lymphoma (T-ALL) and Alport syndrome. In the neurology field, SpringWorks Therapeutics Inc develops therapies for patients with rare neurological diseases that currently have no satisfactory treatment options. An important focus in this area is the development program for Mirdametinib, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with neurofibromatosis type 1 (NF1). In the hematology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare hematological diseases such as myelofibrosis, chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). An important focus in this area is the development program for Senexin A, an inhibitor of protein methyltransferases. This program has the potential to provide a new therapy for patients with myelofibrosis. In the pediatrics field, SpringWorks Therapeutics Inc develops therapies for children with rare and severe diseases such as nephrotic syndrome and epilepsy. An important program in this area is the development program for PD-0325901, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with nephrotic syndrome. Overall, SpringWorks Therapeutics Inc has an impressive pipeline of promising development programs that have the potential to improve the lives of patients with rare and hard-to-treat diseases. Through its close collaboration with other companies, research institutes, and patient organizations, the company is able to effectively and efficiently implement its development plans and thus create better treatment options for patients around the world. SpringWorks Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about SpringWorks Therapeutics stock

How much dividend does SpringWorks Therapeutics pay?

Over the past 12 months, SpringWorks Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SpringWorks Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SpringWorks Therapeutics?

The current dividend yield of SpringWorks Therapeutics is .

When does SpringWorks Therapeutics pay dividends?

SpringWorks Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SpringWorks Therapeutics?

SpringWorks Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SpringWorks Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SpringWorks Therapeutics located?

SpringWorks Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SpringWorks Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SpringWorks Therapeutics from 9/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did SpringWorks Therapeutics pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of SpringWorks Therapeutics in the year 2023?

In the year 2023, SpringWorks Therapeutics distributed 0 USD as dividends.

In which currency does SpringWorks Therapeutics pay out the dividend?

The dividends of SpringWorks Therapeutics are distributed in USD.

Andere Kennzahlen von SpringWorks Therapeutics

Our stock analysis for SpringWorks Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SpringWorks Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.